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ABSTRACT 
Although both chemotherapy and hyperthermia therapy have their inherent advantages, 
the non-specific targeting of chemotherapy and ineffectiveness of hyperthermia therapy 
alone suggests a better method can be developed. To overcome this problem, the 
combined treatment of chemotherapeutic agents with plasmonic photothermal therapy 
(PPTT) is proposed. This is the first study to investigate the efficacy of combined 
chemotherapy and PPTT using monocytes as delivery vehicles for gold nanoshells. The 
results of this investigation shows that PPTT combined with cisplatin resulted in some 
degree of synergism while additive effects were observed for concurrent treatments of 
PPTT and doxorubicin and PPTT and bleomycin. 
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CHAPTER 1 
 
INTRODUCTION 
1.1 Hypopharyngeal Squamous Cell Carcinoma   
Hypopharyngeal cancers are relatively uncommon: each year approximately 
2,500 new cases are diagnosed in the U.S (American Cancer Society, 2014). These 
cancers can be divided into upper hypopharyngeal and lower hypopharyngeal cancers. 
Upper hypopharyngeal cancers are more closely linked with heavy drinking and smoking, 
in comparison to the lower hypopharyngeal, or the postcricoid, cancers which are more 
frequently associated with nutritional deficiencies. Currently, the majority of 
hypopharyngeal cancers are mucosal squamous cell carcinomas (SCC). Current treatment 
for many cancers such as brain, hypopharyngeal squamous cell carcinomas and breast 
include surgical resection of the tumor followed by various concurrent or subsequent 
treatments such as chemo and/or radiotherapy. The goal of subsequent treatments is to 
eliminate the malignant cells residing in the margin surrounding the resection cavity 
thereby reducing or eliminating recurrence.  Unfortunately, in many cases, none of the 
standard treatment regimens have proven to be successful suggesting that alternative 
therapeutic approaches are required. 
 Almost all cancers in the hypopharynx originate from thin, flat cells of squamous 
cells located in the innermost layer of the epidermis (Fig. 1) Cancers originating in this 
layer are called squamous cell carcinoma or squamous cell cancer. Most squamous cell 
cancers begin as a pre-cancerous condition of dysplasia, and when seen under a 
microscope, the cells look abnormal but not yet cancerous. Often this condition resolves 
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on its own without any treatments, especially if the underlying cause is addressed. Most 
patients with dysplasia do not have any symptoms unless it is on the vocal cord. In some 
cases, the dysplasia will progress to carcinoma in situ (CIS). In this condition, the cancer 
cells are seen in the epithelial lining of the hypopharynx, but have not grown into deep 
layers or spread to other parts of the body. Carcinoma in situ is the earliest form of cancer 
and can be cured at this stage. If carcinoma in situ is not treated, it can develop into an 
invasive squamous cell cancer which can destroy nearby tissues and spread to other parts 
of the body. 
 
Figure 1 Right hypopharyngeal wall squamous cell carcinoma extending from the tonsil down to the pyriform sinus 
(Ghorayeb, 2014) 
Clinically, hypopharyngeal cancers have the tendency to be aggressive: they are 
characterized by diffuse local and distant spread and, as such, they tend to metastasize in 
their early stages. In a large study of patients with SCC of the pharynx and hypopharynx, 
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87% of patients with pyriform sinus SCC were found to have stage III or stage IV disease; 
82% of patients with SCC of the posterior pharyngeal wall were found to have stage III 
or stage IV disease (American Cancer Society, 2014).  
 In general, hypopharyngeal cancer treatments are controversial. To some extent, 
this is attributed to its low incidence and the inherent difficulty in conducting adequately 
powered, prospective, randomized clinical studies (Trinidad et al., 2014). For this reason, 
it is difficult to identify the ideal therapy for a specific site or stage for this type of cancer. 
Primary treatment consists of surgery and radiation therapy however, in recent years, 
chemotherapy has been added for some select advanced hypopharyngeal cancers.  
The overall poor prognosis of hypopharyngeal squamous cell carcinomas is due to 
a number of factors including presentation at a late stage, multisite involvement within 
the hypopharynx, unrestricted soft-tissue tumor growth, an extensive regional lymphatic 
network allowing metastases development, and restricted surgical options for complete 
resection. Local and regional recurrences are the most common causes of treatment 
failure. Following a definitive treatment, most failures occur within the first 2 years. In 
addition to the risk of delayed regional metastases, the risk of developing a second 
primary tumor in patients with tumors of the upper aerodigestive tract has been estimated 
to be 4 to 7% per year (American Cancer Society, 2014). Surveillance of patients with 
hypopharyngeal cancer should be lifelong because of these risks. Five year survival rates 
for hypopharyngeal cancer are summarized in Table 1 
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Hypopharynx Cancer Stage 5-year relative survival rate 
I 53% 
II 39% 
III 36% 
IV 24% 
Table 1 Survival rates of hypopharynx cancer by stage (AJCC Cancer Staging Manual, Seventh Edition) 
 
 
1.2 Human Hypopharyngeal FaDu (HTB-43) Head and Neck Cell Monolayer 
An epithelial cell line was established from a hypopharyngeal squamous cell 
carcinoma during the course of a study on the adenovirus-induced T-antigens in human 
oral and pharyngeal tumor tissues. This cell line was named FaDu, in honor of the patient 
from which the tissue was removed. This is a squamous cell carcinoma of the 
laryngopharynx (Grade II) which has been cultured since 1968. After the initial thirty 
serial subpassages, this cell line has retained the epithelial morphology and orderly 
growth as a monolayer sheet. 
From the first tissue culture (Fig. 2), the polygonal-shaped and compactly packed 
epithelial cells migrated out of the explant three days after the beginning of the culture. 
Furthermore, many fibroblastic-type cells were on the outward growth from the explant, 
and many mitotic cells were observed in the peripheral regions of the epithelial 
outgrowth.  The monolayer sheet of cells was obtained from the cellular outgrowths 
similar to the epithelial elements observed in the primary cultures (Fig. 3). Due to the 
early stage difficulties of cellular repopulating in the subpassage cultures, complete 
5 
 
isolation of individual cells from the cell sheet was not achieved until the thirtieth 
passage level.  
 
Figure 2 First passage explant on collagen-coated glass tube 8 days after transfer (Rangan. 1972) 
 Morphologically, the cells were and continue to be epithelial in nature. In phase 
contrast microscopy images, dense granular material in the cytoplasm and around the 
nucleus is seen in the cells at all passage levels (Rangan. 1972). In the monolayer, multi-
layered focal regions of the cells are frequently observed. The average population 
doubling time of the cell line at the 16th passage level was found to be approximately 50 
hours (Fig. 3). With regards to the malignant properties of the cell line, the original study 
by Rangan (1972) showed two of the four ten-day-old chick-chorioallantoic membranes 
seeded with cell suspension developing single discrete nodular growth. From histological 
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studies, the nodules were found to contain identical cellular elements to those in the 
tissue culture.  
 
Figure3 Growth curve of the cell line at the 16th passage level (Rangan. 1972) 
 In the preliminary virus infection studies, the cell line was found to be susceptible 
to some viruses containing either RNA or DNA. In particular, the parainfluenza viruses, 
types 2 and 3 were found to infect the cells. Additionally, cultures infected with 
adenoviruses, type 3 and 12, revealed typical cytopathic changes and numerous 
intranuclear aggregates of virus particles in thick sections of the cell (Rangan, 1972), 
however, the cells were not susceptible to SV40 virus. 
 
1.3 P388D-1 Murine Lymphocytic Monocytes 
 Monocytes are precursor cells that differentiate into macrophages once they have 
migrated from the circulation into the tissue where they reside (Owen et al., 2004; 
Murdoch and Lewis, 2005). In general, macrophages are categorized as white blood cells 
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originating from myeloid progenitor cells of the bone marrow and they are the first to 
mediate host immune responses against foreign objects. In addition to their role in 
phagocytosis of invading pathogens, macrophages also release several growth factors 
such as cytokines and interleukins (e.g. transforming growth factor-β (TGF-β) and 
platelet-derived growth factor), and they are involved in a number of other inflammatory 
responses as well as in the repair of damaged tissues (Metz et al., 2004; Hsiao et al.,  
2008).  
 Macrophages play a central regulatory and effector role in the immune response 
of the body against neoplasia (Fidler et al., 1988). They are transformed into an activated 
state from the resting state in response to a variety of foreign stimuli like bacteria, viruses, 
and tumors. These activated macrophages release TNF, IL-1, nitric oxide, lysozymes, and 
other cytokines which can kill tumor cells and activate the host immune response (Adams, 
1992).   
It has been demonstrated that certain antineoplastic drugs confer a dual 
functionality to macrophages. i.e., these drugs act as both tumoricidal agents and 
immunopotentiators; a well-documented example of this phenomenon is cisplatin. It  has  
been reported  that  murine  macrophages  treated  with  cisplatin  showed  enhanced  
capacity  to  lyse  tumor  cells  in  vitro  and  also  resulted  in  increased  production  of  
IL-1, TNF, reactive oxygen intermediates, reactive nitrogen intermediates, lysozyme and 
arginase (Singh et al., 1991; Alaparthy et al., 1991). Furthermore, P388D-1 cells treated 
with different concentrations of cytosine arabbinoside, vincristine sulphate, 
cyclophosphamide, mitomycin C, and hydroxyl urea showed increased IL-1 activity, and 
enhanced cytotoxicity (Pai et al., 1997).  
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 In addition to neoplastic cells and blood vessels, tumors are also composed of 
leukocytes, specifically macrophages. These macrophages are known as tumor-associated 
macrophages (TAMs) which are monocytes that are recruited into the tumor and 
comprise up to 50% of the tumor’s cellular mass (Murdoch and Lewis, 2005; Knowles 
and Harris, 2007).  In the case of squamous cell carcinomas, the tumor-infiltrating cells 
consist mainly of T lymphocytes, monocytes and macrophages. For a tumor to be able to 
utilize macrophages for their benefit, the macrophages must first be recruited, and to 
achieve this, tumors induce a chemo-attractive gradient by secreting a number of factors, 
the most important of which are chemokines (Choi et al., 2007). 
 Macrophages have become a very attractive carrier for the delivery of therapeutic 
agents due to their inherent ability to migrate and aggregate within and around the tumor, 
especially in hypoxic regions. A key benefit of using a cell-based delivery system is the 
increase in the nanoparticle’s systemic half-life because macrophages act as protectors 
against reticulo-endothelial elimination. From a clinical perspective, the basic procedure 
for such a strategy involves isolation of macrophages from a given patient followed by 
macrophage loading of the agent of interest (e.g. nanoparticles) which are then injected 
into the patient (Owen et al., 2004; Murdoch and Lewis, 2005; Knowles and Harris, 
2007). 
Cell-based vectorization is one method that can target and maintain an elevated 
concentration of nanoparticles at the tumor site and prevent their spread into normal 
tissue (Madsen et al., 2012a). Employing macrophages, in conjunction with nanoparticle 
delivery for plasmonic photothermal therapy (PPTT) has interesting potential for cancer 
treatment since they are attracted to hypoxic and necrotic regions within tumors.  
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Macrophages have been shown to internalize a sufficient number of gold-silica 
nanoshells to be useful for PPTT in in vitro systems consisting of cell monolayers or 3-D 
multicellular spheroids (Baek et al., 2011; Trinidad et al., 2014). 
 
1.4 Plasmonic Photothermal Therapy 
 The use of hyperthermia in the destruction of solid tumors has been under 
investigation for some time. The efficacy of thermal therapy through a variety of heat 
sources including laser light, focused ultrasound, and microwaves has been studied by 
numerous investigators. Compared to normal tissue, tumors have a poor blood supply and, 
therefore a reduced heat tolerance which makes them susceptible to hyperthermia 
treatments. In addition, hyperthermia causes irreversible cell damage by loosening the 
cell membrane and denaturing critical proteins. There are numerous benefits of thermal 
therapy over conventional resection: most approaches are minimally or non-invasive, 
relatively simple to perform, and have the potential of treating embedded tumors in vital 
regions where surgical resection is not feasible. Ultimately, the difficulty of this type of 
therapy is that the activating energy source must have significant penetration into tumor 
tissues while, at the same time, sparing normal tissues. Simple heating techniques have 
difficulties discriminating between tumors and surrounding healthy tissue, and often 
result in the heating of intervening tissue between the source and the target site. Several 
groups have investigated treatment of tumors through hyperthermia using deep 
penetrating near infrared (NIR) lasers with or without contrast enhancing agents, however, 
success with current systems has been modest (Chen et al., 1997; Prudhomme et al., 1996; 
Chen et al., 1996). 
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 The emerging use of laser light to achieve controlled and confined thermal 
damage to the tumor tissue has revolutionized cancer therapy. Lasers have been used in 
medical applications since the 1960s, and the first reports of tumor eradication in 1965 
sparked a wide interest in their use in oncologic applications. The laser light can either be 
transmitted from an optical fiber tip to exposed tumors or be delivered into a confined 
space via insertion of the fiber into the center of the target tumor, which is often called 
interstitial laser hyperthermia (Bown 1983; Steger et al., 1989; Masters and Bown 1990; 
Masters and Bown 1992a; Masters and Bown 1992b). Although reasonable tumor 
selectivity can be achieved with interstitial laser hyperthermia, this is an invasive 
technique. Light absorbing dyes have been used to increase tumor selectivity. Following 
light excitation of the dye molecule, electrons transition from the ground state to the 
excited state. Typically, the dye molecules relax via nonradiative decay channels 
resulting in heating of the local environment around the light absorbing agents. If the 
temperature increase is sufficient, the process leads to localized tissue destruction. The 
photoabsorbing agents can be naturally occurring chromophores in the tissue or 
externally added dye molecules such as indocyanine green, naphthalocyanines, and 
porphyrins coordinated with transition metals (Huang et al., 2008). Unfortunately, natural 
chromophores are characterized by very low absorption and therefore they are inefficient 
hyperthermia agents. A potential solution to this problem is the laser activation of NIR-
absorbing metallic nanoparticles, termed plasmonic photothermal therapy (PPTT) 
(Anderson and Parrish 1983) (Fig 4).  
11 
 
 
Figure 4 NIR light ablated PC3 prostate tumor cells with nanoshell treatment. In vitro cellular ablation with bare gold/ 
gold sulfide nanoparticles following incubation and laser application. Yellow circle indicates the laser spot; live/dead 
stain for viability shows dead cell as red while viable cells appear green. White bars = 100 microns. (Gobin et al., 
2011). 
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Figure 5 Gold nanoshell plasmon resonances for a 120 nm core with indicated shell thickness (Mody et al. 2010). 
  In recent years, the rapid development of nanotechnology has provided a variety 
of nanostructures with unique optical properties that may prove useful in biology and 
biomedical applications (El-Sayed, 2001; Katz and Willner 2004). From the cancer 
therapy point of view, noble metal nanoparticles are very useful PPTT agents due to their 
enhanced absorption cross sections, which are four to five orders of magnitude larger 
than those offered by conventional photoabsorbing dyes which make them more effective 
photothermal coupling agents (Huang et al., 2008). Nanoshells are a new class of 
optically tunable nanoparticles composed of a dielectric core (silica) coated with an 
ultrathin metallic layer of gold (Oldenburg et al,. 1999). Through adjusting the thickness 
of the core and shell, nanoshells can be manipulated to absorb or scatter light at a desired 
wavelength across visible and NIR wavelengths (Fig.  5). This optical tunability permits 
the fabrication of nanoshells with a peak optical absorption in the NIR, a region of light 
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where optical penetration through tissue is optimal (Weissleder, 2001). In general, the 
efficacy and stability of the metal shell on the nanoshell converts absorbed light to heat 
with an efficiency that far exceeds that of conventional dyes. Furthermore, the absorption 
properties of the nanoshells are dependent upon the material’s rigid metallic structure 
rather than the more labile molecular orbital electronic transition of conventional dyes, 
which in turn makes the nanoshells less susceptible to photobleaching. The efficacy of 
nanoshells as a NIR absorber has already been demonstrated in a series of in vivo 
magnetic resonance thermal imaging (MRTI) studies examining temperature profiles of 
nanoshell-loaded tumors irradiated with NIR light. These studies found that nanoshells 
absorbed NIR light and generated increased temperatures sufficient to produce 
irreversible photothermal damage to subcutaneous tumors (Hirsch et al., 2003a).  
 To improve the biocompatibility of the nanoshells, ‘stealthing’ polymers like 
poly(ethylene glycol) (PEG) can be crafted to nanoshell surfaces using simple molecular 
self-assembly techniques (Hirsch et al., 2003b). It has been demonstrated that stealthing 
liposomes as well as other biomolecules and materials with PEG suppresses 
immunogenic responses, improving blood circulation times and overall material/implant 
performance (Chen and Scott 2001; Harris et al., 2001).  
 In PPTT electromagnetic radiation (usually in the visible to near-infrared 
wavelengths) incident on gold-based nanoparticles is converted to heat and, as such, this 
technique can be used as a therapeutic approach to destroy cancer cells. The maximum 
absorption wavelength depends on a number of factors including nanoparticle 
composition, size and geometry. Ideally, nanoparticles should demonstrate significant 
absorption in the near-infrared since this wavelength region has high penetration in 
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biological tissues (Trinidad et al., 2014). This provides the rationale for using gold-silica 
nanoshells with silica core diameters of 120 nm and gold shells of 15 nm thickness as 
they have maximum light absorption around 800 nm. In addition to their favorable 
absorption properties, 150 nm gold-silica nanoshells are also ideally suited for passive 
delivery to tumors via the enhanced permeability and retention (EPR) effect 
(Puvanakrishnan, 2012). Preferential accumulation of 20-300 nm particles in tumors 
occurs due to the leaky tumor vasculature (enhanced permeability) and poor lymphatic 
drainage (enhanced retention). 
The efficacy of chemotherapeutic agents is sensitively dependent on the ability to 
deliver these compounds in therapeutic concentrations to the tumor site. Most 
chemotherapeutic agents demonstrate a high efﬁcacy with a variety of tumors. 
Nevertheless, nonspeciﬁc delivery leads to signiﬁcant normal tissue toxicities and limits 
dosages to levels far below those required to destroy most malignancies. To overcome 
this problem, the combined treatment of chemotherapeutic agents with PPTT is proposed. 
Heat treatment, called hyperthermia, has been demonstrated to augment the cytotoxicity 
of some chemotherapeutic agents, resulting in similar cure rates and reduced morbidity 
with lower drug doses (Hahn et al., 1975; Hildebrandt et al., 2002; Jones et al., 2005; 
Tang and McGoron 2009). 
 
1.5 Bleomycin 
 One of the anti-cancer agents under investigation for this research is a 
chemotherapeutic compound called bleomycin (BLM) (Fig 6). Bleomycin is a 1.5 kDa 
glycopeptide antibiotic produced from the bacterium Streptomyces verticillus. It was 
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discovered by Umezawa et al. in 1966 and was found to be cytotoxic to eukaryotic cells 
due to its ability to induce DNA breaks (Suzuki, 1970). Bleomycin is typically used for 
the treatment of squamous cell carcinomas of the head and neck, esophagus, bronchus, 
and skin, as well as testicular cancer and Hodgkin’s and non-Hodgkin's lymphoma (Mir 
et al.,1996; Berg et al.,2005).  Side effects include pneumonitis (in 46% of patients) and 
lung fibrosis (in 3% of patients) which can occur after a cumulative dose of 300 mg m-2 
(Mir et al., 1996). Patients are typically treated two to three times per week or given a 
continuous low dose for several days.  The drug has a biological half-life in blood of 2-4 
hours after intravenous injection, with 70% excreted after the first 24 hours (Mir et al., 
1996 ).  
 
Figure 6 Structure of bleomycin. (Barber et al. 1981) 
 Bleomycin has a large hydrophilic structure comprised of four major parts: 
terminal amine, bithiazole, pseudopeptidic, and glycannic (Mir et al., 1996).  The 
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terminal amine group interacts with nucleic acids, anchoring the bleomycin to the double 
helix strand. The bithiazole domain serves to bind with DNA and interacts with the DNA 
minor groove. The pseudopeptidic group is responsible for binding to transition metals 
and functions as DNA sequence selectivity and strand cleavage. Last, the function of the 
glycannic domain is still under investigation. Bleomycin forms metal oxide complexes by 
both binding to oxygen as well as redox-active transition metal ions Fe2+, Co2+, Zn2+, 
Ni2+, and Cu2+ (Suzuki, 1970).  Bleomycin has been shown to amass in endocytic 
vesicles and has limited ability to penetrate the cell membrane.  Hence, bleomycin 
typically enters the cell through receptor-mediated endocytosis by binding to a 250 kDa 
membrane receptor (Berg et al., 2005).  Though bleomycin generally demonstrates some 
potency once inside the cell, it still needs to diffuse through the nuclear membrane in 
order to interact with the DNA. 
 The primary biochemical action of bleomycin is through induction of DNA strand 
breaks, and some suggest bleomycin inhibits incorporation of thymidine into the DNA 
strand (Van Meir et al., 2010). In vitro, bleomycin DNA cleavage depends on oxygen and 
metal ions, but the exact mechanism of DNA strand scission is still unresolved. It has 
been suggested that bleomycin chelates metal ions, primarily iron, producing a 
pseudoenzyme that reacts with oxygen to produce superoxide and hydroxide free radicals 
which can cleave the DNA. An alternative hypothesis proposes that bleomycin may bind 
at specific sites in the DNA strand and induce scission through abstracting the hydrogen 
atom from the base, which would result in strand cleavage as the base undergoes a 
Criegee-type rearrangement or forms an alkali-labile lesion (Quada et al., 1998). The 
intracellular response to bleomycin damage is illustrated in Figure 7. 
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Figure 7 Intracellular response network to bleomycin damage (Chen and Stubbe, 2005) 
 
1.6 Doxorubicin 
 Doxorubicin is the trade name of the liposomal formulation Doxil, also known as 
hydroxydaunorubicin (Fig. 8). It is an anthracycline antibiotic, closely related to the 
natural product daunomycin. Like all anthracyclines, it works by intercalating DNA, with 
the most serious adverse effect being life-threatening heart damage (Tacar et al., 2013). It 
is commonly used in the treatment of a wide range of cancers, including hematological 
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malignancies, soft tissue sarcomas and many types of carcinomas, including those of the 
breast (Tacar et al., 2013).  
 
Figure 8 Structure of doxorubicin 
 Doxorubicin interacts with DNA by intercalation and inhibition of 
macromolecular biosynthesis (Hahn et al., 1975). This inhibits the progression of the 
enzyme topoisomerase II, which relaxes supercoils in DNA for transcription (Pigram et 
al., 1972). Doxorubicin stabilizes the topoisomerase II after it has broken the DNA chain 
for replication which prevents the DNA double helix from being resealed and therefore 
stops the process of replication. The planar aromatic chromophore portion of the 
molecule intercalates between two base pairs of the DNA, while the six-membered 
daunosamine sugar sits in the minor groove and interacts with flanking base pairs 
immediately adjacent to the intercalation site, as evidenced by several crystal structures 
(Pang et al., 2013). By intercalation, doxorubicin can also induce histone eviction from 
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chromatin. As a result, DNA damage response, epigenome and transcriptome are 
deregulated in doxorubicin-exposed cells (Tang and McGoron, 2009). A summary of the 
action of doxorubicin is illustrated in Figure 9. 
 
Figure 9 Action of doxorubicin in a stylized cancer cell. (Thorn et al. 2010) 
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1.7 Cisplatin 
 Cisplatin is one of the most potent antitumor agents known, displaying clinical 
activity against a wide variety of solid tumors. Cisplatin, cisplatinum, or cis-
diamminedichloridoplatinum(II) (CDDP) is a member of a class of platinum-containing 
anti-cancer drugs which now also includes carboplatin and oxaliplatin (Fig. 10). These 
platinum complexes react in vivo, binding to and causing crosslinking of DNA, which 
ultimately triggers apoptosis (programmed cell death) (Pruefer et al., 2008) 
 
Figure 10  Structure of cisplatin 
 Cisplatin’s cytotoxic mode of action is mediated by its interaction with DNA to 
form DNA adducts, primarily intrastrand crosslink adducts, which activate several signal 
transduction pathways, including those involving ATR, p53, p73, and MAPK, and 
culminate in the activation of apoptosis (Fig. 11). DNA damage-mediated apoptotic 
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signals, however, can be attenuated, and the resistance that ensues is a major limitation of 
cisplatin-based chemotherapy (Siddik. 2003). Cisplatin induces DNA crosslinks in 
several different ways thereby interfering with cell division by mitosis. The damaged 
DNA elicits DNA repair mechanisms, which in turn activate apoptosis when repair 
proves impossible (Liu et al., 2008). Most notable among the changes in DNA are the 
1,2-intrastrand cross-links with purine bases. These include 1,2-intrastrand d(GpG) 
adducts which form nearly 90% of the adducts and the less common 1,2-intrastrand 
d(ApG) adducts (Matysiak et al., 2009). 1,3-intrastrand d(GpXpG) adducts occur but are 
readily excised by nucleotide excision repair (NER). Other adducts include inter-strand 
crosslinks and nonfunctional adducts that have been postulated to contribute to cisplatin's 
activity (Matysiak et al., 2009). Interaction with cellular proteins, particularly HMG 
domain proteins, has also been advanced as a mechanism of interfering with mitosis, 
although this is probably not its primary method of action (Matysiak et al., 2009). 
Cisplatin  also  activates  human  natural  killer cells  and  monocytes  and  
upregulates  interleukin-2-induced  lymphokine  activated killer  cells  (Sodhi et al., 
1992). It is thought that cisplatin-mediated  cancer  remission  is  a  combined  outcome  
of  its  immunostimulating and  cytotoxic  effects. (Pai et al., 1997).  
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Figure 11 Mechanisms involved in inhibiting the apoptotic signal in cisplatin-resistant tumor cell (Siddik. 2003) 
   
1.8 Scope of Work 
 The purpose of this research is to investigate the combined effects of a number of 
commonly used chemotherapeutic agents (bleomycin, doxorubicin, cisplatin) with gold-
silica nanoshell- induced hyperthermia on a human head and neck cancer cell line. This 
will be accomplished by comparing the toxicity of each treatment (chemotherapy or 
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photothermal therapy) with the combined treatment. In the proposed in vitro studies, 
macrophages will be used as nanoshell delivery vehicles.  
For comparative purposes, a separate set of experiments will be performed 
employing a conventional hyperthermia technique in which the monolayers will be 
exposed to elevated temperatures in an incubator. In all cases, a cell proliferation 
colorimetric assay will be used to determine therapeutic efficacy.   
 
Figure 12 Model of macrophage endocytosis of nanoparticles and incorporation into tumor spheroids followed by 
laser-mediated thermal ablation (Makkouk and Madsen 2013)  
Hypothesis: The combined macrophage-mediated chemo-thermal treatment will yield 
greater cell toxicity than individual treatments consisting of either chemotherapy or 
photothermal therapy. The increased cell toxicity will be similar to that observed in 
monolayers subjected to combined chemotherapy and conventional hyperthermia. 
There are two particularly novel aspects associated with the proposed work: (1) the 
use of nanoshell PPTT-induced hyperthermia combined with chemotherapeutic 
agents, and (2) macrophage-mediated delivery of nanoshells. 
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CHAPTER 2 
 
MATERIALS AND METHODS 
2.1 Cell Lines 
All experiments were performed in vitro utilizing a human hypopharyngeal 
squamous cell carcinoma line (FaDu) and murine lymphocytic monocytes (P388D-1). All 
work was done inside a Labconco Class II Biohazard Cabinet (Labconco Corp., Kansas 
City, MO) at the University of Nevada, Las Vegas (UNLV) unless otherwise specified.  
Cells were incubated at 37°C, 5.0% CO2, and 95% humidity inside a VWR incubator 
(VWR International, LLC. West Chester, PA).  The cell line was kept in Gibco 
Dulbecco’s Modified Eagle medium (DMEM) (Invitrogen Corp., Carlsbad, CA) with 
10% heat-inactivated fetal bovine serum (FBS), 25 mM HEPES buffer (pH 7.4), and 
penicillin (100 U/ml). All monolayer cells were sub-cultured using the same technique.  
After checking the confluence, the T-75 flask was emptied of all media and the 
cells washed with 5 ml of Gibco phosphate buffered saline (PBS) with pH of 7.2 
(Invitrogen Corp., Carlsbad, CA). Next, 5 mL of Gibco 0.25% Trypsin-EDTA 
(Invitrogen Corp., Carlsbad, CA) was added and the flask slowly rocked approximately 
twenty times. The trypsin was removed after 5 min. Trypsin is a proteolytic enzyme, 
which functions to detach adherent cells from the flask surface.  Following the 5 min. 
trypsin incubation, 5 mL of DMEM was added to the flask and the suspended cell media 
was pipetted up and down several times to ensure the separation of cells. Thereafter, 2 
mL of the media was added to 13 mL of fresh DMEM inside a new T-75 flask. Two 
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flasks were seeded in this fashion to ensure a consistent supply of cells for the 
experiments.  
 
2.2 Monolayer Plating 
 The monolayer plating consisted of a mixture of FaDu cells and P388D1 murine 
monocytes loaded with gold nano-shells (AuroShell™), purchased from Nanospectra 
Biosciences Inc. (Houston, TX). Gold nanoshells (4.3 x 109) were incubated with 
monocytes (2.0 x 105 cells ml-1) under standard conditions for 24 h prior to the cell 
plating. After 24 h of incubation, monocytes were treated with mitomycin C for one hour 
to prevent cell division. Monocytes were washed twice with PBS in order to remove non-
ingested nanoparticles and mitomycin C residues.  
On the day of plating, FaDu cells (70% confluence) were harvested from the 
growth flask and transferred to a 15 ml centrifuge tube with 11ml of DMEM with a cell 
concentration of 20,000 FaDu cells ml-1 (Total of 2.2 x 105 cells). 1.1 x105 loaded 
monocytes were added to the 15 ml centrifuge tube making the ratio of FaDu-to-murine 
monocytes 2:1. The 15 ml centrifuge tube was slightly vortexed for 10 seconds to achieve 
better mixing of the cells. The cell solution was then transferred to a 50 ml reservoir and 
100 µl of the cell solution was placed in each well of a 96-well plate resulting 2,000 
FaDu cells and 1,000 monocytes per well. 
For the chemo agent toxicity plates and heat simulation experiment, each well in 
the 96-well plate was filled with the cell solution except the 12th column which was left 
empty. 
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2.3 Cell Proliferation Assay (MTS) 
The CellTiter 96®  AQueous One Solution Cell Proliferation Assay (Promega, 
Madison, WI) is a colorimetric method for determining the number of viable cells in 
proliferation or cytotoxicity assays. The CellTiter 96®  AQueous One Solution Reagent 
contains a novel tetrazolium compound [3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium], inner salt,  MTS, and an 
electron coupling reagent (phenazine ethosulfate; PES). PES has enhanced chemical 
stability, which allows it to be combined with MTS to form a stable solution. The MTS 
tetrazolium compound is bioreduced by cells into a colored formazan product that is 
soluble in tissue culture medium (Figure 13). This conversion is presumably 
accomplished by NADPH or NADH produced by dehydrogenase enzymes in 
metabolically active cells. The quantity of formazan product, as measured by absorbance 
at 490 nm, is directly proportional to the number of living cells in culture. The 
absorbance at 490 nm in each well is measured using a microplate reader.  
 
 
Figure 13 Chemical Structure of MTS to Formazan 
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For every measured 96 well plate, 30µl of MTS reagent was added into each well 
containing cells. 150 µl DMEM and 30µl of MTS reagent were added into each well of 
the 12th column of each plate. This last column contained no cells and thus provided a 
measure of the background noise of the MTS assay. The plates were incubated in the 
VWR incubator for one hour. After incubation, the plates were transferred to an Infinite®  
M1000 PRO microplate reader (TECAN Group Ltd., Männedorf, Germany) for 
absorbance reading at 490 nm. The results were recorded on Microsoft Excel worksheets. 
 
2.4 Drug Toxicity 
The FaDu cell/nanoshell-loaded P388D1 murine monocyte suspension was 
injected into each well of a 96-well plate (except the 12th column). A total of three well 
plates were prepared (one for each chemotherapeutic drug). Drugs were added to DMEM 
medium to obtain concentrations of: 0.1-10 µg ml-1 (bleomycin), 0.001-0.05 µg ml-1 
(doxorubicin) and 1-75 µg ml-1 (cisplatin). The drugs were added to each well in 7 of the 
11 columns containing the cell/loaded monocyte suspension 24 h after the initial cell 
seeding. Two non-drug columns served as positive and negative controls, respectively 
while two columns containing cell mixtures were unused. Typically, each column (eight 
wells) on a plate contained one drug concentration. In all cases, suspensions and 
chemotherapeutic agents were incubated for five days in an incubator (VWR 
International, LLC. West Chester, PA). Following incubation, 0.1 ml of 90% ethanol was 
added to each well of one of the non-drug columns (eight wells total) of each of the three 
plates. These columns served as positive controls since ethanol is toxic to cell 
suspensions. Any signal emanating from these wells was considered background noise, 
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i.e., a reference point for total cell death. Following the 15 min. ethanol incubation, MTS 
assays were performed to determine viability. The MTS reagent (30 µl) was added to 
each well and after 60 min incubation, the plate was placed in a microplate reader 
(Infinite®  M1000 PRO) and the fluorescence emission from each well was recorded. The 
background signal (MTS column #12) and the ethanol treated column was subtracted 
from each well and the resultant signal was normalized to the signal from the negative 
control group, i.e., the column containing no drugs (cell suspensions only). The 
pharmacological potency resulting in approximately 60-90% survival was used in 
subsequent combined therapy studies. 
 
2.5 Photothermal Toxicity 
A fiber-coupled diode laser (Intense, North Brunswick, NJ) was used to irradiate 
cells at a wavelength of 805 nm. Each well was irradiated separately using an irradiance 
of 7 W cm-2. Three irradiation times were investigated: 5, 7.5 and 10 min corresponding 
to radiant exposures of 2.10, 3.15 and 4.20 kJ cm-2. The radiant exposure resulting in 
approximately 90% survival was used in subsequent combined therapy studies. All 
irradiations were performed in a specially designed incubator in order to maintain 
physiological conditions, in which the incubator was kept at a constant temperature of 37 
oC and acetic acid was added to sodium bicarbonate for CO2 production. The 600 µm dia.  
optical fiber (Model FD1; Medlight, Ecublens, Switzerland) connected to the diode laser 
was inserted through an opening at the top of the incubator and cells in individual wells 
of the 96-well plate were irradiated by placing the fiber in contact with the bottom of the 
plate (irradiation beam diameter = 8 mm). Only every third column and every third row 
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of the well plate contained cells resulting in a total of 12 wells per plate and a total of two 
plates for this experiment. The empty wells provided a barrier preventing scattered light 
from irradiating cells in adjacent wells.  As previously described, the 12th column 
contained MTS reagent and no cells and one column with cells served as positive control. 
After the irradiation, the plates were incubated in the VWR incubator for 5 d. Following 
incubation, MTS assays were performed as previously described. The background signal 
from the MTS-only column and the ethanol treated column was subtracted from the 
treatment columns and results are normalize to the no PPTT treatment control group.  
 
2.6 Combined Chemo- and Photothermal Treatment 
Based on the toxicity results for each of the three drugs, concentrations resulting 
in 70-90 % survival were chosen, i.e., 5 µg ml-1 bleomycin, 10 µg ml-1 cisplatin, and 
0.005 µg ml-1 doxorubicin were added to the combined FaDu cells and P388D1 murine 
monocytes monolayer in the 96 well plates prior to the irradiation; Only every third 
column of the well plate contained cells, resulting in a total of 6 wells per treatment 
group and 12 wells per plate. The empty wells provided a barrier preventing scattered 
light from irradiating cells in adjacent wells. The control groups were established with the 
same concentrations of chemo agents as in the corresponding combined PPTT and chemo 
treatment groups in one 96 well plate (eight well total for each group) and were 
maintained in the VWR incubator for the duration of the trial. Each photothermal treated 
well was irradiated separately using an irradiance of 7 W cm-2 (8 mm beam diameter) for 
7.5 minutes resulting in a radiant exposure of 3.15 kJ cm-2. Otherwise, the irradiation 
protocol using the 805 nm fiber-coupled diode laser was identical to that previously 
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described in section 2.5. Following treatment, the plates were incubated for 5 d and MTS 
assays were performed at the end. The background signal from the MTS-only column and 
the ethanol treated column was subtracted from the treatment columns, and results were 
normalized to the no treatment control group.  
 
2.7 Conventional Hyperthermia 
 Bleomycin (5 µg ml-1), cisplatin (10 µg ml-1), and doxorubicin (0.005 µg ml-1) 
were added to the combined FaDu cells and P388D1 murine monocytes monolayer in 
three 96 well plates (total of eight wells per drug in each plate) prior to the hyperthermia 
treatments. As previously described, the interval between cell seeding and addition of 
drugs was 24 h. Immediately thereafter, each 96-well plate was placed in the specially 
designed irradiation incubator for 45 min. at one of three temperatures: 37, 41 or 44 oC. 
During the 45 min. treatment, aceticylic acid was added to sodium bicarbonate for CO2 
production. Following treatment, each plate was transferred to the main incubator After 5 
d of incubation, the MTS assay was performed. The background signal from the MTS-
only column and the ethanol treated column was subtracted from the treatment columns 
and results were normalized to the 37 oC no-drug control group.   
 
2.10 Statistical Analysis 
Data analysis was performed in Microsoft Excel. All data were normalized to the 
control group of each individual experiment and all error bars represent standard 
deviations. In order to determine the degree of interaction between PPTT and the chemo-
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agents the following equation was used (Drewinko et al. 1976 – not found in reference 
section – please add): 
𝛼 =
𝑆𝐹𝑃𝑃𝑇𝑇 𝑥 𝑆𝐹𝐶ℎ𝑒𝑚𝑜
𝑆𝐹𝑃𝑃𝑇𝑇+𝐶ℎ𝑒𝑚𝑜
 (Eq. 1) 
The numerator includes the product of the surviving fraction (SF) of the individual 
treatments separately and the denominator includes the surviving fraction of the 
combined treatments. A value of α=1 indicates an additive effect. A value of α < 1 or α > 
indicates an antagonistic or synergistic effect, respectively.  
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CHAPTER 3 
 
RESUTLS 
3.1 Drug Toxicity  
In order to determine the optimal drug levels for evaluating the effects of 
combined chemotherapy and PPTT, titrations were performed for each drug. The results 
are shown in Figures 14 – 16 for each respective chemotherapeutic agent. In all cases, the 
surviving fraction was normalized to the negative (no drug) controls. As expected, the 
results show a decrease in survival with increasing drug concentrations. As illustrated in 
Figure 14, the 50% survival dose (LD50) for doxorubicin in this cell mixture is 
approximately 0.0075 µg ml-1. All cells were killed at a concentration of 0.05 µg ml-1.  
The bleomycin titration results (Figure 15) show that the LD50 is approximately 5 
µg ml-1 which is lower than the corresponding value for cisplatin (Figure 16). 
Collectively, the data show that, for this particular cell line, doxorubicin has the highest 
toxicity while cisplatin is the least toxic. Based on the previously established criterion of 
60-90% survival, the results in Figures 14-16 suggest that doxorubicin, bleomycin and 
cisplatin, concentrations of 0.005, 5, and 10 µg ml-1, respectively should be used in the 
combined treatments. 
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Figure 14 Doxorubicin toxicity titration from 0.001 to 0.05 ug ml-1. Each data point represents mean ± standard 
deviation.  
 
 
 
Figure 15 Bleomycin toxicity from 0.1 to 10 ug ml-1  Each data point represents mean ± standard deviation. 
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Figure 16 Cisplatin Toxicity titration from 1 to 75 ug ml-1  Each data point represents mean ± standard deviation. 
 
 
3.2 Photothermal Toxicity   
As illustrated in Figure 17, a 7 W cm-2 irradiance had little effect on overall 
survival for the treatment times investigated: irradiation times of 7.5 and 10 min. resulted 
in only 15% cell kill. Based on these results, an irradiation time of 7.5 min. was chosen 
for the combined PPTT and chemotherapy studies. 
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Figure 17 Photothermal therapy potency using fiber-coupled diode laser at 810 nm. Each data point represents mean ± 
standard deviation. 
 
3.3 Combined Chemo- and Photothermal Treatment  
As illustrated in Figure 18, surviving fractions for bleomycin, cisplatin, and 
doxorubicin were 68.2 ± 5.7 %, 68.1 ± 4.43%  and 81.8 ± 3.9 % respectively. The 
toxicity of photothermal therapy was 79.4 ± 11.2 %. Surviving fractions for combined 
photothermal and chemo treatments were 65.08 ± 10.2 %, 49.2 ± 5.1 %, and 30.9  ± 5.8 
% for doxorubicin, bleomycin and cisplatin, respectively. The corresponding alpha values, 
calculated from equation 1 are shown in Table 2. The alpha values suggest slight additive 
effects for the PTT + doxorubicin and PTT + bleomycin combinations, while a 
synergistic effect was noted for the PTT + cisplatin treatment. 
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Figure 18 Combined chemo and photothermal treatment. Surviving fraction was normalized to the positive (no 
treatment) controls. Each data point corresponds to the mean and standard error of three trials.   
 
Trial Group α 
PPTT + doxorubicin 0.005 µg ml-1 0.83±0.19 
PPTT + bleomycin 5 µg ml-1 1.09±0.20 
PPTT + cisplatin 10 µg mL-1 2.10±0.50 
Table 2 Alpha values of combined chemo and photothermal treatments 
 
3.4 Conventional Hyperthermia 
As shown in Figure 19, surviving fractions for doxorubicin, bleomycin, and 
cisplatin at 37 ̊ C were 87.7 ± 4.1 %, 78.2 ± 3.5% , and 66.9 ± 5.4 % respectively. 
Surviving fractions for cells exposed to 41 and 44 oC were 88.0 ± 5.2 % and  95.4 ± 2.4%, 
respectively. Surviving fractions for combined 41 oC hyperthermia and chemo treatments 
were 86.2 ± 2.6 %, 81.4 ± 3.4 % , and 67.6 ± 7.6 % for doxorubicin, bleomycin and 
cisplatin, respectively. The corresponding values for combined treatments at the higher 
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temperature (44 oC) were 65.4 ± 3.0 %, 51.0± 4.2 % , and 37.3 ± 8.8 %. The 
corresponding alpha values calculated from equation 1 are shown in Table 3. Alpha 
values for the combined treatments at the lower temperature (41 oC) suggest a slight 
additive effect while, at the higher temperature, a small degree of synergism is observed 
for each drug.  
 
 
Figure 19  Combined hyperthermia and chemotherapy treatments for three different drugs. Survival fraction was 
normalized to the positive (no treatment) controls. Each data point represents mean ± standard deviation. 
 
 
Trial Group (41 ̊C) α Trial Group (44 ̊C) α 
Heat + doxorubicin 0.005 µg 
 ml-1 
0.89±0.07 Heat+Doxorubicin 0.005 µg ml-1 1.28±0.11 
Heat + bleomycin 5 µg ml-1 0.85±0.07 Heat + bleomycin 5 µg ml-1 1.46±0.16 
Heat + cisplatin 10 µg mL-1 0.87±0.13 Heat + Cisplatin 10 µg ml-1 1.71±0.43 
Table 3 Alpha values of combined hyperthermia and chemo treatments 
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CHAPTER 4 
 
DISCUSSION 
Current treatment for many cancers such as brain, hypopharyngeal squamous cell 
carcinomas and breast cancers include surgical resection of the tumor followed by 
various concurrent or subsequent treatments such as chemo and/or radiotherapy. The goal 
of subsequent treatments is to eliminate the malignant cells residing in the margin 
surrounding the resection cavity thereby reducing or eliminating recurrence.  
Unfortunately, in many cases, none of the standard treatment regimens have proven to be 
successful suggesting that alternative therapeutic approaches are required. This research 
investigated the utility of combining traditional chemotherapy agents with nanoshell 
mediated laser-induced hyperthermia in an in vitro system consisting of murine 
monocytes and human hypopharyngeal cancer cells.  
Chemotherapy is one of the standard treatment options for cancer patients.  The 
efficacy of chemotherapeutic agents is sensitively dependent on the ability to deliver 
these compounds in therapeutic concentrations to the tumor site. Most chemotherapeutic 
agents demonstrate a high efﬁcacy with a variety of tumors. Nevertheless, nonspeciﬁc 
delivery leads to signiﬁcant normal tissue toxicities and limits dosages to levels far below 
those required to destroy most malignancies. Heat treatment, called hyperthermia, has 
been demonstrated to augment the cytotoxicity of some chemotherapeutic agents, 
resulting in similar cure rates and reduced morbidity with lower drug doses (Hahn et al., 
1975; Hildebrandt et al., 2002; Jones et al., 2005; Tang and McGoron, 2009) 
Hyperthermia treatments have been under clinical investigation for some time. 
Compared to normal tissues, tumors are more susceptible to hyperthermia because of 
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their poor blood supply and subsequent reduced heat tolerance. Furthermore, heat 
modifies the cytotoxicity of many chemotherapeutic agents. The extent of ‘thermal 
chemosensitisation’ both in vitro and in vivo can be quantified by comparing tumors 
treated with drug alone and those treated with a combination of drug and hyperthermia. 
Several studies have shown S-phase specific cell lethality of cells exposed to a variety of 
chemotherapeutic agents (Grisham et al., 1980). Observations suggest that moderate heat 
treatment itself does not induce chromosomal DNA strand breaks directly, but can alter 
chromatin structure influencing DNA repair (Kampinga and Dikomey, 2001). In addition, 
heat treatment induces both apoptosis and necrosis, and the form of death changes from 
apoptosis to necrosis above a certain threshold temperature (Harmon et al., 1990). 
To overcome the non-specific targeting of chemotherapy, the combined treatment 
of chemotherapeutic agents with PPTT is proposed. This is the first study to investigate 
the efficacy of combined chemotherapy and PPTT using monocytes as delivery vehicles 
for gold nanoshells.  
The effects of bleomycin, cisplatin and doxorubicin have been investigated in a 
wide variety of cancer cell lines. For example the LD50 for bleomycin in a F98 rat glioma 
cell line ranged from 0.5 to 0.75 µg ml-1 (Mathews et al., 2012; Madsen et al., 2009) 
while the corresponding values in human breast carcinomas was between 0.75 and 1.75 
µg ml-1 (Mathews et al., 2012). These values are significantly lower than the LD50 
observed for bleomycin in the present study employing the FaDu cell line (5 µg ml-1). 
The LD50 for cisplatin in three human breast cancer cell lines (MCF-7, MDA-MB-435 
and MDA-MB-231) was approximately 93 µg ml-1 while for doxorubicin it was 10 – 20 
µg ml-1 in the MCF-7 cell line and 0.5 – 0.75 µg ml-1 in the MDA-MB-435 and MDA-
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MB-231 breast cancer lines (Mathews et al., 2012).  In comparison, the LD50 in FaDu 
cells was approximately 15 and 0.0075 µg ml-1 for cisplatin and doxorubicin, respectively. 
Differences in LD50 values between the present work and the results of Mathews et al. 
(2012) are likely due to the different cell lines investigated. The observation that different 
cell lines have wide varying sensitivities to chemotherapeutic agents is illustrated in the 
doxorubicin data of Mathews et al. (2012) which show that, even for the same type of 
cancer (breast), there can be a significant variation in sensitivities to chemotherapeutic 
drugs. Other reasons for the observed differences between the present study and those of 
others include differences in: (1) survival assays (MTS vs. clonogenic survival) and (2) 
growth conditions.      
In all cases, low drug concentrations resulted in survival fractions exceeding 
100%. This was likely due to a phenomenon known as hypergenesis in which cancer cells 
are stimulated to divide in response to external stimuli.  
PPTT has been shown to be very effective for inducing rapid temperature 
elevations in tumors containing NIR absorbing gold nanoshells while minimizing damage 
to surrounding normal tissues. Since squamous cell carcinomas of the head and neck 
contain significant concentrations of macrophages, these tumors are ideally suited for 
macrophage-mediated therapies (Trinidad et al., 2014). Both stromal and tumor cells 
produce a wide variety of chemokines and growth factors which have the ability to recruit 
circulating monocytes and differentiate them into macrophages (Lewis and Pollard, 2006; 
Galdiero et al., 2013). The tendency of macrophages to migrate and accumulate in tumors, 
especially hypoxic regions, makes them attractive delivery vectors for both therapeutic 
and diagnostic agents including nanoparticles.  
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PPTT-induced cytotoxic effects depend on the total light energy (radiant exposure) 
delivered. Therefore, higher incident laser powers (irradiances) allow for shorter 
treatment times. For example, doubling the irradiance reduces the treatment time by one-
half. Effective PPTT requires temperatures in the range of 46 to 60 oC, however, higher 
temperatures may be required in hypoxic, low pH environments found in many tumors 
(Huang et al., 2008.). PPTT efficacy is dependent on a number of factors, including light 
distributions in tissues. Due to the limited penetration depth of 810 nm light in brain 
tissues (0.5 – 1.0 cm; Madsen and Wilson 2012), PPTT may require direct light delivery 
via optical fibers. In addition to the light distribution, the concentration of nanoparticles 
in the tumor tissue is also important and should be optimized to produce sufficient 
temperature elevations for efficient PPTT (Trinidad et al., 2012). Since PPTT is oxygen-
independent, it’s ideally suited for the treatment of tumors with high fractions of hypoxic 
cells.  
A number of studies have demonstrated the efficacy of PPTT using gold 
nanoshell loaded macrophages or monocytes in in vitro systems consisting of human 
glioma spheroids (Baek et al., 2011; Chhetri et al. 2014.) and human head and neck 
squamous carcinoma cell lines (Trinidad et al. 2014).  The results of Trinidad et al. (2014) 
are particularly relevant to the present work since the same cell line (FaDu) was used. 
The irradiation parameters (7 W cm-2; 5 – 10 min. exposures) and FaDu to monocyte 
ratio (2:1) used in the present study were chosen based on the results of Trinidad et al 
(2014) who showed that an irradiance of 7 W cm-2 for 5 min. (radiant exposure of 2.1 kJ 
cm-2) resulted in approximately 95% survival in a 2:1 mixture of FaDu cells and 
nanoshell-loaded macrophages. This is in excellent agreement with the results presented 
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in Figure 17. Trinidad et al. (2014) found that significant cytotoxicity (20% survival) 
required irradiances of 28 W cm-2 delivered over 5 min. (radiant exposure of 8.4 kJ cm-2) 
These investigators also observed no cytotoxicity in empty macrophages exposed to 8.4 
kJ cm-2. A similar finding was noted by Chhetri et al. (2014) who found no growth 
inhibition in human glioma spheroids subjected to identical radiant exposures. 
Collectively, these results suggest that a radiant exposure of 8.4 kJ cm-2 is insufficient to 
produce hyperthermic effects in cells devoid of nanoshells. Based on these results, a 
laser-irradiated only control group of FaDu cells was deemed unnecessary.  
The results in Figure 17 show that PPTT is a very inefficient treatment modality. 
For example, a radiant exposure of 4.2 kJ cm-2 produced only 15% cell kill. In 
comparison, a radiant exposure of 0.75 J cm-2 used in photodynamic therapy, resulted in 
50% survival of FaDu cells (Trinidad et al., 2014). As previously discussed, the 
advantage of PPTT is that, unlike photodynamic therapy, it is an oxygen-independent 
treatment modality and, as such, it is useful for the treatment of hypoxic cells.  
In order to investigate the degree of interaction between the chemotherapeutic 
agents and PPTT, suboptimal levels of both modalities were determined. The results 
(Figure 18 and Table 2) show an additive effect (α ≈ 1) with concurrent treatments of 
both PPTT and bleomycin and PPTT and doxorubicin. A synergistic effect (α > 1) was 
noted for concurrent PPTT and cisplatin. The mechanism of synergism is not known, but 
it likely has several components. Most importantly, all three drugs are incorporated into 
DNA causing damage which often results in cell death unless the damage is repaired. 
Since hyperthermia inhibits DNA repair, it’s postulated that the addition of heat enhances 
the cytotoxicity of the chemotherapeutic agents via inhibition of DNA repair. 
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PPTT-induced hyperthermia was compared with conventional incubator-induced 
hyperthermia. The conventional hyperthermia data (Figure 19, Table 3) show that the 
degree of interaction between the two modalities was sensitively dependent on 
temperature: at 41 oC, all interactions were additive (or mildly antagonistic), while at 44 
oC all interactions were weakly synergistic. These results are in qualitative agreement 
with studies showing additive effects for doxorubicin and synergistic effects for 
bleomycin and cisplatin at 43.5 oC (Issels, 2008). The reason for the differences in alpha 
values between the PPTT and conventional hyperthermia data is not known, but it’s 
likely due to a temperature threshold effect. As illustrated in Table 3, synergistic effects 
are more likely at higher temperatures. Since temperatures were not recorded during the 
PPTT treatments, it’s possible that the laser irradiation parameters chosen were 
insufficient to induce the threshold temperatures required for synergism with bleomycin 
and doxorubicin.   
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CHAPTER 5 
 
CONCLUSIONS 
 The overall objective of the work was to investigate the effects of combined 
PPTT and chemo agents on monolayers of FaDu hypopharyngeal squamous cell 
carcinoma. Suboptimal levels of both drugs and PPTT were determined. The results 
showed that PPTT combined with cisplatin resulted in some degree of synergism while 
additive effects were observed for concurrent treatments of PPTT and doxorubicin and 
PPTT and bleomycin. Concurrent treatments of conventional hyperthermia and 
chemotherapeutic drugs demonstrated that the degree of interaction between the two 
modalities was sensitively dependent on temperature: only additive (or mildly 
antagonistic) interactions were observed at 41 oC while weakly synergistic interactions 
were observed in all three cases at the higher temperature (44 oC). Compared to the 
standard hyperthermia data, the lack of synergism between PPTT and bleomycin and 
PPTT and doxorubicin might be due to an inability to attain the required temperature 
threshold with the chosen laser irradiation parameters. In future experiments, this 
discrepancy might be resolved by careful monitoring of temperatures during PPTT.  
Although mechanistic studies were not performed, the likely explanation for the 
observed synergism is the ability of hyperthermia to inactivate DNA repair mechanisms 
thus resulting in increased cell death. This could be investigated in future studies using 
chemotherapeutic agents that do not interact directly with DNA.  Performing these 
experiments in other cell lines may also shed some light on the mechanisms of action. 
Finally, in vivo studies should be performed to evaluate the effectiveness of the combined 
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treatments. This is important since vascular effects will most certainly play a major role 
in the tumor’s response to these treatments. 
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